Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 17/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16554677 | 0.91 | CD274 (1.00) | CD274MEN1KMT2A | |
| SCHEMBL17889728 | 0.88 | CD274 (1.00) | CD274 | |
| SCHEMBL16555134 | 0.88 | CD274 (0.79) | CD274PDCD1 | |
| SCHEMBL16554928 | 0.86 | CD274 (1.00) | CD274 | |
| SCHEMBL5098455 | 0.83 | CD274 (0.71) | CD274MEN1KMT2AAKT1 | |
| SCHEMBL5105512 | 0.83 | MEN1 (0.77) | CD274MEN1KMT2A | |
| SCHEMBL16555131 | 0.80 | CD274 (1.00) | CD274PDCD1 | |
| SCHEMBL5098986 | 0.80 | CD274 (0.66) | CD274MEN1KMT2AAKT1 | |
| SCHEMBL16554899 | 0.80 | CD274 (1.00) | CD274PDCD1 | |
| SCHEMBL5096313 | 0.78 | KMT2A (0.66) | CD274MEN1KMT2AAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9872852-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-23 | — | — | US | disclosed |
| US-9872852-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-23 | — | — | US | disclosed |
| US-20160194307-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-07-07 | — | — | US | disclosed |
| US-20160194307-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194307-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | CD74, HAVCR2, CD4 | CD274 121/4885MEN1 1811/4885KMT2A 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.